SOM3355 — a medicine approved for high blood pressure and chest pain — is being tested in a Phase 2 trial as a means to treat chorea in Huntington’s disease patients, SOM Biotech announced. The proof-of-concept study (NCT03575676) will recruit participants in four clinical sites in or near Barcelona, Spain.
News
Targeting specific genes involved in inflammation and cellular structure may be a therapeutic strategy to reduce protein clumps in patients with Huntington’s disease, according to researchers. Their study, “High-Throughput Functional Analysis Distinguishes Pathogenic, Nonpathogenic, and Compensatory Transcriptional Changes in Neurodegeneration,” appeared in the journal Cell…
Retrotope’s investigative therapy RT001 reduced cognition deficits in mice with Huntington’s disease, and was found to lower the amount of oxidative damage in their brains. The study, “Deuterium‐reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington’s disease,” was published in…
News
Improved Genetic Testing Protocols Should be Available for Huntington’s Disease, Study Contends
Adequate support and follow-up should be considered when implementing and designing pre-symptomatic genetic testing for Huntington’s disease, a study has revealed. The study, “Perspectives on Genetic Testing and Return of Results from the First Cohort of Presymptomatically Tested Individuals At Risk of Huntington Disease,” was published in…
Skyhawk Therapeutics and Celgene have entered into a five-year global partnership to use Skyhawk’s STAR* technology platform to discover, advance, and commercialize new small-molecule therapies to treat patients with neurological diseases, including Huntington’s disease. The STAR* approach, which stands for “small-molecule therapies for alternative splicing in RNA,” aims to correct the…
The Scottish region of Fife has launched one of the world’s first local care frameworks for Huntington’s disease, putting local staff and families at the forefront of work to help those with this neurodegenerative disease. The launch, at Victoria Hospital, saw families affected by Huntington’s join health and social…
Improved measures to accurately determine the effectiveness of treatments targeting Huntington’s disease are necessary, according to clinical neurologists and Huntington’s specialists. The editorial, “Improved metrics for Huntington’s disease trials,” reflects on recent advances made for the development of targeted agents that can effectively change the course of Huntington’s disease.
Impaired metabolism of a type of brain cell called an astrocyte plays an important role in the development and progression of Huntington’s disease, a study using a mouse model has found. Discovery of this previously unknown error could be key in developing future treatments for Huntington’s, which does…
A new therapeutic strategy based on a small part of the huntingtin protein — which in a mutated form is responsible for Huntington’s disease — shows potential to regulate the course of disease, according to a study using mice. The study, “Improvement of BDNF signalling by P42…
A key protein in Huntington’s disease has damaging effects on heart function beyond the disease’s devastating neurological impact, according to researchers. Their study, “Cardiac mTORC1 Dysregulation Impacts Stress Adaptation and Survival in Huntington’s Disease,” was published in the journal Cell Reports. Huntington’s disease is…
Recent Posts
- The invisible battle of staying present with Huntington’s disease
- Combining 2 drugs could slow nerve cell death in Huntington’s: Study
- Your voice matters to the Huntington’s disease community
- Tiny systems that keep my life moving with Huntington’s disease
- UK company selects HRN001 as its lead Huntington’s therapy candidate